RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 CEES
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 11
SP 7
OP 7
DO 10.1177/1559897715593515
UL http://mdc.sagepub.com/content/15/11/7.2.abstract
AB A 6-week, open-label trial of a controlled-release formulation of the central nervous system stimulant methylphenidate achieved a dose that, when delivered in the evening, lessens attention deficit hyperactivity disorder symptoms in the morning in children aged 6 to 12 years. Moreover, symptoms are controlled for much of the remaining day.